David Hotchkiss, MD
Cardiovascular Disease · Port Charlotte, FLNPI 1548377435
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,648 of the $17,542 with a category attached, or 60.7%. It is spread thinly across 44 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2022 at $4,647 and has fallen 69.3% since, to $1,426 in 2025.
Across 421 payments — averaging $41.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Eli Lilly$2K
- Novartis$2K
- Medtronic$2K
- Biotronik Inc.$1K
- Bayer$1K
- plus $5K from 38 others
Across 292 payments — averaging $13,702 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.9M
- Janssen Research & Development, LLC$754K
- Novartis$678K
- AstraZeneca$191K
- Amgen$144K
- Merck$105K
- plus $202K from 8 others
What the payments were for
- Consulting fees$1,81310%
- Travel & lodging$4,94628%
- Food & beverage$10,64861%
- Education$1351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Anthem CRT Pacemaker$1,813
- LEQVIO$1,072
- Micra$464
- Pulsar-18 T3$435
- MitraClip$267
- Supera peripheral stent system$229
- SUPERA$134
- RotarexS 6 F x 135 cm$133
- Omnilink Elite vascular stent system$129
- Passeo-18$118
- Azure$108
- GENERAL VASCULAR INTERVENTION$107
- BioMonitor$105
How this compares
$17,542 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 994 | $1,257,016 |
| EntrestoSacubitril/Valsartan | 247 | $372,798 |
| XareltoRivaroxaban | 267 | $369,593 |
| MultaqDronedarone Hcl | 135 | $184,491 |
| Repatha SureclickEvolocumab | 77 | $94,105 |
| FarxigaDapagliflozin Propanediol | 35 | $42,058 |
| BrilintaTicagrelor | 32 | $27,971 |
| Praluent PenAlirocumab | 20 | $18,330 |
| JardianceEmpagliflozin | 11 | $14,137 |
| NexlizetBempedoic Acid/Ezetimibe | 18 | $13,325 |
| Metoprolol Succinate | 882 | $11,930 |
| Rosuvastatin Calcium | 745 | $11,000 |
| Ezetimibe | 339 | $7,951 |
| Losartan Potassium | 654 | $5,299 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $5,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $324 | $1,257,016994 claims |
| NovartisEntresto | $1,894 | $372,798247 claims |
| Johnson & JohnsonXarelto | $357 | $369,593267 claims |
| Sanofi-aventis U.S. LLCMultaq | $164 | $184,491135 claims |
| AstraZenecaFarxiga, Brilinta | $92 | $70,02967 claims |
| Boehringer IngelheimJardiance | $59 | $14,13711 claims |
| Esperion Therapeutics, Inc.Nexlizet | $189 | $13,32518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Port Charlotte
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.